Versant Ventures launches Vector BioPharma with USD 30m Series A
12 August 2022 – Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that is devoid of viral genes. Versant has made a USD 30m Series A commitment to Vector BioPharma, which is the most recent company to emerge out of the firm’s Ridgeline Discovery Engine based in Basel, Switzerland.
Walder Wyss advises Versant Ventures in connection with the launch of Vector BioPharma. The team includes Alexander Gutmans (Partner, Transaction/M&A & Venture Capital), Karina Tschon (Associate, Transaction/M&A & Venture Capital), Manuel Bigler (Managing Associate, IP/Licensing) and Lucas Maurer (Associate, Transaction/M&A & Venture Capital).